热门资讯> 正文
ImmunityBio获得8000万美元融资
2025-07-25 18:10
- ImmunityBio (NASDAQ:IBRX) has secured new financing to provide further working capital and support its ongoing business operations.
- The company entered into a securities purchase agreement with two institutional investors for a registered direct offering, which includes the sale of common stock and accompanying warrants to purchase additional shares.
- The deal is expected to generate around $80 million in gross proceeds at closing.
- If the warrants are fully exercised, the company could receive up to an around $96 million in gross proceeds.
- IBRX +2.9% premarket to $3.1
- Source: Press Release
More on ImmunityBio
- ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval
- ImmunityBio: High Stakes On Anktiva's Growth Amidst FDA Friction And Financial Pressures
- ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze
- ImmunityBio gets FDA expanded access authorization to treat lymphopenia with Anktiva
- ImmunityBio upgraded to Overweight at Piper Sandler on Anktiva success
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
